Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030966 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
NCT00030966 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 1,200 participants.
The verdict
NCT00030966, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
Interventions
- DRUG Placebo
- DRUG Natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2002-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030966
The ClinicalTrials.gov registry entry for NCT00030966 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00030966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030966 about?
NCT00030966 is a clinical study titled "Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis". The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
What is the current status of trial NCT00030966?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2002-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00030966?
The interventions under investigation include: Placebo (DRUG), Natalizumab (DRUG).
Who is sponsoring clinical trial NCT00030966?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.